epiDx®

epiDx® is a blood-based liquid biopsy test for the diagnosis of breast cancer based on the epigenetic differences between breast cancer and healthy individuals.

1 in 13 women will get breast cancer in their lifetime.

Breast cancer is the most common cancer in women worldwide.

Current standard of care for breast cancer screening is mammography, which is a painful and a patient – unfriendly process that leads to low screening participation rates. High potential to overdiagnosis and overtreatment.

Image for reference purpose only.

INEX's Solution

epiDx® is a blood-based liquid biopsy test for the diagnosis of breast cancer based on the epigenetic differences between breast cancer and healthy individuals.

USER-FRIENDLY

Simple blood draw to collect sample for testing.

EARLY DETECTION

Early detection is the key to successful cancer treatment. User-friendly screening process would result in higher screening participation and earlier detection rate of cancer.

ASIAN-FOCUSED

epiDx® is the first-ever test to stratify Asian patients regardless of sub-type and stage of breast cancer with high specificity and sensitivity.

  1. SCS, 2021. Breast Cancer. Singapore Cancer Society. Available at: https://www.singaporecancersociety.org.sg/learn-about-cancer/types-of-cancer/breast-cancer.html
  2. Autier, P. and Boniol, M., 2018. Mammography screening: a major issue in medicine. European Journal of Cancer90, pp.34-62.
INTERESTED?

If you're interested in epiDx® and would like to know more or partner with us, let's chat.